Clinical study of Wuling capsule combined with nucleoside analogues in the treatment of chronic hepatitis B hypoviremia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200006471

Enrollment

Unknown

Registered

2022-08-14

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B hypoviremia (syndrome of liver depression and spleen deficiency with blood stasis)

Interventions

Treatment group:Wuling capsule combined with nucleoside (acid) analogues

control group:nucleoside (acid) analogues

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Age 18~65 (2) Patients with chronic hepatitis B hypoviremia (HBV DNA 20~2000 iu/ml) can be diagnosed in combination with previous medical history (3) TCM syndrome differentiation is liver depression and spleen deficiency with blood stasis; (4) Patients who voluntarily sign informed consent

Exclusion criteria

Exclusion criteria: (1) Patients with other virus infections (HAV, HCV, HDV, HEV, CMV, EBV, HIV); (2) Patients with severe hepatitis and liver cancer such as drug liver, alcoholic liver disease or nonalcoholic fatty liver; (3) Pregnant or lactating patients; (4) Patients who have participated in other clinical trials or participated in other drug clinical trials for less than 1 month

Design outcomes

Primary

Measure	Time frame
Serum HBVDNA load;Energy alt, AST, GGT, ALP, TBIL, DBIL;	—

Secondary

Measure	Time frame
TCM symptom score;	—

Countries

China

Contacts

Public ContactNan Yuemin

nanyuemin@163.com18533112266

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026